The importance of dose intensity has been suggested in ovarian carcinoma. We retrospectively evaluated the long-term results of melphalan-based high-dose chemotherapy (HDC) with hematopoietic rescue in a unicentric series of 33 patients with advanced ovarian cancer sensitive to first-line chemotherapy. Before HDC, treatment with debulking surgery and platinum-based chemotherapy was followed by second-look operation (SLO). HDC consisted of melphalan (n = 8), melphalan and cyclophosphamide (n = 9), or melphalan, etoposide and carboplatinum (n = 16). Toxicity was mainly hematological. One death occurred from infection during aplasia. With a median follow-up of 60 months after intensification, the 5-year progression-free survival (PFS) rate was 29% and the 5-year overall survival (OS) rate was 45%. Survival differed significantly according to tumor status at SLO. Women with microscopic or macroscopic disease at SLO, ie with a pathological partial response to first-line therapy (PPR), had survivals of 7% at 5 years, similar to other salvage therapies. Better results were obtained in the 20 women with a complete pathological response (PCR) at SLO with 43% 5-year PFS (median, 51 months) and 75% 5-year OS (median not reached). In conclusion, melphalan-based HDC with hematopoietic rescue had an acceptable toxicity in patients with chemosensitive advanced ovarian cancer. In situations of salvage therapy for patients in PPR, this treatment was not effective in long-term analysis. On the contrary, long-term results were favorable in patients with PCR, suggesting further prospective randomized studies comparing HDC and other consolidation treatments should be undertaken in this particular situation. Bone Marrow Transplantation (2000) 26, 61-67.
Despite recent progress in current treatment combining cytoreductive surgery and platinum-based chemotherapy, the prognosis for advanced ovarian carcinoma remains disappointing with a 5-year survival of 20% and a median of 20 to 40 months. 1, 2 However, this tumor is sensitive to firstline chemotherapy with nearly 80% complete clinical response (CCR) and 40% pathological complete response (PCR). However, the majority of responding patients will subsequently develop chemoresistant recurrence and die.
To overcome this resistance, several therapeutic strategies have been envisaged, including the use of the doseresponse effect of chemotherapy. The dose-response relationship has been well demonstrated with alkylating agents, 3 and the development of hematopoietic growth factors and hematopoietic stem cell support (HSCS) has permitted their use in high-dose chemotherapy (HDC) regimens for several years. Among the agents applicable to large dose escalation, melphalan has been used in several malignancies and has shown a high antitumor activity with acceptable toxicity. 4, 5 Ovarian carcinoma is a favorable candidate for HDC and HSCS for three reasons. First, it is chemosensitive, in particular to alkylating agents, most of which have an essentially hematological toxicity which can be controlled by HSCS. Second, dose-response and dose intensity have been demonstrated with these drugs in this disease. 6 Third, bone marrow metastases are exceptional during evolution of this cancer so that graft contamination is unlikely.
The first pilot studies of HDC with HSCS in ovarian carcinoma 7, 8 were realized in conventional chemotherapy refractory patients and proved its feasibility and tolerability, with an encouraging response rate. With doses multiplied by factors of 5 to 10, toxicity was tolerable and the response rate of 40 to 80% was superior to that of classical salvage chemotherapy (10 to 30%). Thus, with conventional doses, the plateau of the dose-response curve was not reached, implying that part of the chemoresistance may be overcome by dose intensification. Nevertheless, this treatment has not had a favorable impact on survival because of the short duration of the responses (3 to 9 months), demonstrating the high rate of acquired resistance during a long treatment evolution. These observations lead us to suppose that if this treatment were delivered earlier in the course of the disease, as a consolidation treatment just after first-line chemotherapy and to smaller and still chemosensitive tumors, the results in terms of toxicity and survival could improve as already demonstrated for hematological malignancies. From 1983, in our institution, patients with advanced ovarian carcinoma sensitive to first-line chemotherapy as documented at second-look laparotomy were enrolled in pilot studies of HDC with HSCS in order to complete or consolidate the antitumor effect. We report the long-term results in a cohort of 33 patients treated between January 1983 and March 1996 with melphalan-based HDC.
Materials and methods

Patient selection
To be eligible for this study, patients were required to have a histological diagnosis of epithelial ovarian carcinoma at an advanced stage (III or IV FIGO) with proof of sensitivity to first-line chemotherapy documented during the secondlook operation (SLO). Other eligibility criteria included age of 65 years or less, WHO performance status less than grade 3, adequate end organ function: renal (creatinine clearance у60 ml/min), hepatic (serum bilirubin and transaminases Ͻ1.5 times normal), cardiac (left ventricular ejection fraction Ͼ50%), respiratory (carbon monoxide diffusion capacity Ͼ50% of normal) and hematological (WBC count Ͼ3.5 × 10 9 /l, Hb level Ͼ100 g/l, platelet count Ͼ100 × 10 9 /l). Patients with other types of tumour or with psychiatric disease were excluded, as were patients with cerebral metastases or active infection at the time of stem cell harvesting. Patients had to have undergone a bone marrow harvest yielding greater than 2 × 10 8 mononuclear cells/kg or a peripheral blood harvest yielding greater than 2 × 10 6
CD34
+ cells/kg. Before study enrollment, all patients underwent laparotomy for staging and maximum debulking surgery, followed by cisplatinum-based combination chemotherapy. After this initial treatment, chemosensitivity of the disease suggested by complete clinical remission (physical examination, serum CA125 level, imaging workup) was confirmed by a SLO. We considered the disease as chemosensitive when this SLO showed a pathological complete response (PCR) or a pathological partial response (PPR). PCR was defined as the complete disappearance of all macroscopic disease with negative peritoneal washings and negative multiple random biopsies. PPR included cases with persistent macroscopic disease but with a у50% reduction of the sum of the perpendicular diameters of all measurable disease (named 'macroscopic disease') and cases with complete disappearance of all macroscopic disease but with positive biopsies (named 'microscopic disease').
High-dose chemotherapy and hematopoietic rescue
Several chemotherapy regimens based on high-dose alkylating agents were used between 1983 and 1996 in phase I-II studies. All patients received high doses of melphalan (140 mg/m 2 ) on day −1 relative to stem cell reinfusion: it was delivered alone (MEL regimen) as already described, 8 or in association with cyclophosphamide (60 mg/kg once daily on days −3 and −2 for a total dose of 120 mg/kg) in the CYM regimen, with carboplatinum (300 mg/m 2 once daily on days −6, −5, −4 and −3 for a total dose of 1200 mg/m 2 ) and etoposide (250 mg/m 2 on days −6, −5, −4 and −3 for a total dose of 1000 mg/m 2 ) in the CARBOMEL regimen. Chemotherapy was administered through a central venous catheter with forced hydration (5% dextrose in semi-saline at 3 l/m 2 /day). Intravenous mesna was added to prevent hemorrhagic cystitis for patients who received high-dose cyclophosphamide.
Hematological rescue consisted of autologous hematopoietic stem cells. From 1983 to February 1994, these cells were collected from bone marrow under general anesthesia, after hematological recovery following a cycle of chemotherapy, according to a technique already described. 9 After this date, they were harvested from peripheral blood by leukapheresis, primed by a cycle of chemotherapy and subsequent subcutaneous recombinant granulocyte colony-stimulating factor (rG-CSF; Amgen, Thousand Oaks, CA, USA). After collection, cells were cryopreserved in dimethylsulfoxide, except when using the regimen of melphalan alone when they were stored at room temperature for 24 h before reinfusion. 4 Quality and quantity of the collection were monitored in every case. Stem cells were reinfused on day 0. Available only since 1992, hematopoietic growth factor (rG-CSF) was administered on day 0 until the neutrophil count exceeded 0.5 × 10 9 /l for 3 consecutive days following aplasia.
Supportive care
Patients were managed in single rooms with reverse isolation and all had a central venous catheter. Transfusions of irradiated blood products (15 Gy) were administered for hemoglobin levels less than 80 g/l, for anemia symptoms, for platelets counts less than 20 × 10 9 /l, or for hemorrhagic symptoms. Febrile episodes (temperature Ͼ38°C for more than 4 h) were immediately treated after cultures with i.v. broad-spectrum antibiotics, associated with i.v. antifungals if fever persisted for more than 4 days. Parenteral nutrition was given if oral intake was inadequate. All patients were discharged from the hospital when their neutrophil and unsupported platelet counts reached 1 × 10 9 /l and 50 × 10 9 /l, respectively, in the absence of suspected or documented complications.
Toxicity evaluation and statistical analysis
The common WHO criteria were used to grade toxicity following high-dose therapy. After treatment, monitoring of patients included physical examination, serum CA125 level and imaging workup. Responses were not assessable because all patients had clinical complete response before HDC and third-look operations were omitted. Progressionfree and overall survivals (PFS and OS) were measured from the date of diagnosis until disease progression or death from any cause, respectively. The Kaplan-Meier method was used for construction of survival curves. The prognostic impact on survival of different factors was analyzed: age (р or Ͼ40 years), initial FIGO stage (III or IV), size of initial tumor residue (р or Ͼ2 cm), pathological response (PR) assessed at SLO (complete, PCR or partial, PPR), high-dose chemotherapy regimen (with or without carboplatinum). On univariate analysis, the log rank test was used to compare data from each group and a multivariate analysis was conducted using Cox's proportional hazards modeling. A P value Ͻ0.05 was considered significant.
Results
Patients and high-dose chemotherapy regimens
Thirty-three women with chemosensitive epithelial ovarian carcinoma, FIGO stages III and IV, were included in this analysis. Their characteristics are listed in Table 1 . Median age was 48 years (range, 23 to 63). The initial surgery was complete or optimal (residual tumor р2 cm) in nine patients and suboptimal (residual tumor у2 cm) in 24 patients of whom 12 had biopsy only. All patients were pre-treated using platinum-based chemotherapy without paclitaxel for a median of six cycles (range, 4 to 11). All had subsequently had a SLO which documented chemosensitivity: most (20 out of 33) were in pathological complete Bone Marrow Transplantation response; 13 were partial responders and had tumor residues at SLO (two microscopic and 11 macroscopic residual tumors). Additional debulking surgery was performed when possible in these patients. Subsequently, patients received one to two courses of standard chemotherapy, similar to treatment given prior to second surgery while waiting for chemotherapy intensification. During this interval, no patient had clinical disease progression. High-dose chemotherapy and stem cell transplantation were undertaken in these patients at a median of 8 months (range, 7 to 14) after diagnosis and 2 months after secondlook surgery. Three different HDC regimens were used: melphalan alone (MEL regimen; n = 8), melphalan and cyclophosphamide (CYM regimen, n = 9), melphalan, etoposide and carboplatinum (CARBOMEL regimen, n = 16). Hematopoietic stem cell support consisted of bone marrow cells in 20 patients (2 × 10 8 mononuclear cells/kg was the minimum to be reinfused) and peripheral blood stem cells in 13 patients (PBSC: minimum 2 × 10 6 CD34 + cells/kg). Sixteen patients received G-CSF after HSC reinfusion.
At the time of this analysis, median follow-up after chemotherapy intensification was 60 months (range, 32 to 126 months) for women alive at last contact.
Toxicity
After high-dose chemotherapy, all patients experienced prompt and severe marrow aplasia (Table 2) . Neutrophil recovery у0.5 × 10 9 /l was achieved overall at a median of 14 days (range, 8 to 28) and an unsupported platelet count у20 × 10 9 /l at a median of 21 days (range, 0 to 100). Recent patients whose stem cells were collected from peripheral blood had faster hematological recovery than did patients who received bone marrow stem cells: neutrophils reached у0.5 × 10 9 /l at a median of 12 days (range, 8 to 16) and 13 days (range, 9 to 29) respectively (not statistically significant) and platelets reached у20 × 10 9 /l at a median of 14 days (range, 0 to 42) and 24 days (range, 12 to 100) respectively (statistically significant, P = 0.03).
All patients developed fever during aplasia, requiring systemic treatment with i.v. antibiotics and/or antifungals. Bacteremia was documented in 12 patients. One patient (3%) died on day 12 after transplantation from fulminant streptococcus septicemia leading to multiple organ failure.
Non-hematological toxicities were never life-threatening. Alopecia was universal, as were nausea and vomiting which Figure 1 ). Several predictive factors for survival were analyzed (Table 3, Figure 2 ): good tumor status at SLO (ie complete vs partial pathological response) was found to be significantly and independently associated with better survival (PFS and OS) on multivariate analysis. Thus, when patients received HDC and HSCS while they were in complete pathological response, they had a 5-year PFS of 43% (95% CI, 19.0-66.9; median 51 months) and an OS of 74% (95% CI, 54.5-93.5; median not reached) vs 7% (95% CI, 0.0-22.1; median PFS 18 months and OS 22 months) for patients in partial pathological response (P Ͻ 0.001 for PFS and OS). The other factors evaluated (age, FIGO stage, initial tumor residue, HDC regimen) were not statistically associated with survival on uni-or multivariate analysis. (1) and progression-free survival (2) . PPR group (pathological partial response; n = 13): overall survival (3) and progression-free survival (4).
Discussion
All women in this study had a tumor sensitive to first-line chemotherapy as documented by second-look laparotomy; 20 had a complete pathological response and 13 a partial pathological response. In the whole population, this consolidation treatment allowed a progression-free survival of 29% after 5 years (median, 29 months) and an overall survival of 45% (median, 54 months). To our knowledge, this series is the largest single center series reported with such a long follow-up and with a conditioning regimen which was melphalan-based in all patients. Despite progress in chemotherapy and in multidisciplinary management of ovarian carcinomas, the prognosis of patients with advanced stages (FIGO III/IV) remains poor. Even if it is now clear that second-look laparotomy does not offer a therapeutic benefit per se, such surgical staging after chemotherapy has a well defined impact on long-term prognosis: women with low tumor burden or no residual tumor have a better outcome than do patients with large residual tumors. 10 However, even good responders to initial chemotherapy, almost universally platinum-based, often have a poor prognosis due to secondary re-evolution of the residual tumor. Such relapses are generally chemoresistant and remain the major cause of death. Thus, it is tempting to treat chemosensitive patients, easily identified by secondlook laparotomy, when residual disease is small or absent, in an effort to kill residual clones and avoid the chemoresistant relapse. Different consolidation therapies can be considered: conventional maintenance chemotherapy, intraperitoneal treatment with chemotherapy and/or immunotherapy, radiation therapy, HDC with HSCS. This latter, 'late intensification treatment', has been widely used in the context of poor risk hematological malignancies and more recently in chemosensitive solid tumors such as metastatic breast cancer.
11
For such consolidation, we used high-dose melphalanbased chemotherapy followed by stem cell transplantation. Melphalan is an ideal alkylating agent to incorporate in HDC regimen for patients with ovarian cancer: it is active in this tumor at a standard dose 12 which can be safely escalated when associated with hematopoietic rescue. Doseresponse relationships have been well documented with melphalan in ovarian carcinoma cell lines, animal models and in clinical settings. 4, 13, 14 We, and others, showed that a dose of 140 mg/m 2 resulted in a broad spectrum of antitumor activity in metastatic cancers, including ovarian carcinoma. 4, 15, 16 In this analysis of consecutive patients melphalan at a dose of 140 mg/m 2 was initially used alone and then combined with drugs active in high doses in ovarian carcinoma: cyclophosphamide, etoposide and carboplatinum. Other reasons to consider these alkylating agents in combination were: the absence of overlapping non-hematological toxicity, different mechanisms of action allowing maximal cytotoxic effect and avoiding cross resistance, 17 a synergistic anticancer cytotoxicity. 18 Currently, in accordance with published results of short series, no regimen has emerged which is clearly superior in ovarian carcinoma. However, results with melphalan are encouraging and among alkylating drugs amenable to large dose escalation, it remains one of the drugs of reference.
Bone Marrow Transplantation
The main toxic effect of melphalan and other alkylating agents in high doses is hematologic. Stem cell transplantation was used to limit the duration of aplasia. It is now clear that this duration is shorter with the use of peripheral blood stem cells (PBSC) as opposed to marrow cells and that such practice is cost-effective. 19 We observed a similar result for platelets in our series when we compared the first cohort of patients who received marrow cells with the more recent patients who received G-CSF-primed PBSC. Thus, this hematological toxicity would probably have been less serious if all our patients had received PBSC and hematopoietic growth factor. However, severe infection can always occur during grade 4 neutropenia and remains the major potential risk during severe aplasia: one of our patients experienced fulminant streptococcus sepsis, as previously reported. 20 As the only case of toxic death in our study, it supports the 3% rate reported by Weaver et al. 21 In this study of 33 patients sensitive to first-line chemotherapy, use of HDC with HSCS resulted in a 5-year PFS of 29% and a 5-year OS of 45% with median of 29 and 54 months, respectively. There were major differences according to tumor status at SLO. For the 13 patients with positive second-look surgery (partial responders to first-line chemotherapy), most (n = 11) with macroscopic disease, we expected HDC to result in salvage in this situation known for its bad prognosis. Unfortunately, our cocktails of alkylating agents did not result in prolonged survival, with 7% 5-year PFS (median, 18 months) and 7% 5-year OS (median, 22 months). Other studies have evaluated salvage strategies for patients with positive second-look surgery and to date long-term results are similar to ours with 5-year survivals inferior to 15% and a median less than 18 months. 22 They have been reported with several conventional chemotherapies, 23 intraperitoneal chemotherapy and/or immunotherapy with interferon, 24, 25 whole abdominal radiation therapy 23, 26, 27 and even HDC and HSCS. 16, 28, 29 The poor prognosis of our 13 patients along with the abovementioned observations implies that no presently known salvage therapy is clearly superior to any other in this situation. Further investigation is needed, focusing particularly on the improvement of PCR rate after first-line chemotherapy.
On the contrary, intensification with HDC and HSCS resulted in significantly better outcomes in our cohort of 20 patients with PCR, with 43% 5-year PFS and 75% 5-year OS. There are conflicting data in the literature for patients with PCR. On one hand, even without treatment, these patients are significantly better off than are patients without PCR, with 5-year survival rates reported between 45% and 65%. 30, 31 On the other hand, several therapeutic approaches have been assessed after PCR has been obtained: maintenance standard chemotherapy, 31, 32 intraperitoneal treatment, 33 radiation therapy, 34 and high-dose chemotherapy with hematopoietic support. Concerning HDC in PCR situations (Table 4) , published unicentric studies are rare 16, 29 and concern less than 20 patients. Moreover, in the series of Lotz et al, 29 including 16 women with PCR and six with a tumor smaller than 2 cm at secondlook laparotomy, survival for the group with PCR was not stated. In the series of Legros et al, 16 19 women underwent intensification in situations of PCR, resulting in a 5-year included nine women treated with high-dose melphalan: results given after a short follow-up of 27 months after intensification showed an OS of 70%. In the summary of the US experiment of HDC in ovarian cancer reported by Shpall et al 28 concerning 249 transplants, 42 were undertaken in patients in complete remission, but with no details concerning clinical or pathological remission, and results were after a short follow-up. Globally, even if all these consolidation treatment studies are uncontrolled, and if it is difficult to interpret and compare results because of heterogeneous populations and treatments, small cohorts and short follow-ups, the 5-year survival rates between 35% and 75% are similar to each other and to our present unicentric study. However, our series of 20 patients, relatively homogeneous in terms of initial prognosis and high-dose treatment, had several features associated with poor prognosis such as many stage IIIC-IV disease (60%), histological grade 2-3 (90%) and tumor residue more than 2 cm at initial surgery (55%). Thus, the results we achieved with a long-term follow-up of 60 months are encouraging.
Finally, these data suggest a value for intensification in ovarian carcinoma in the event of complete pathological response after first-line therapy. But it is difficult to say if this strategy gives better results than do other therapeutic approaches: no treatment, maintenance standard chemotherapy, intraperitoneal treatment, or radiation therapy. In order to discriminate between the available therapies, prospective randomized studies are mandatory, especially in PCR patients. On the other hand, to improve the initial complete pathological response rate, the essential prognostic factor for survival, developments in HDC are progressing in several directions: incorporation of taxanes, 35 intensification of first-line therapy 36 and in sequential strategy, now possible with hematopoietic support. 37, 38 It is likely that improvements will be observed using these strategies and including high-dose melphalan. Several pilot studies are currently underway.
